Podcast Episodes
Back to Search348: Cuts, ousters and drama at the FDA
STAT’s FDA reporter Lizzy Lawrence joins to discuss her inside-the-agency reporting on how Robert F. Kennedy Jr. forced top FDA officials to resign a…
1 year, 6 months ago
347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival
Adam, Elaine, and Allison discuss the Trump administration’s plan for huge job cuts and a restructuring of the country’s top health care agencies, th…
1 year, 6 months ago
346: Zealand's obesity strategy and Immunovant's curious development plan
We chat about positive data from Immunovant's autoimmune drug candidate, a patient death linked to Sarepta's gene therapy, and dispatches from our ST…
1 year, 7 months ago
345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies
We bring on our colleague Sarah Owermohle to discuss the White House's sudden move to withdraw the nomination of Dave Weldon as its pick to run the C…
1 year, 7 months ago
344: Trump's FDA commissioner nominee takes the hot seat
Will Marty Makary be confirmed as the next commissioner of the Food and Drug Administration? Will he bring back employees laid off by DOGE? And what …
1 year, 7 months ago
343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs
It’s a STAT reporter two-fer guest episode. First, Lizzy Lawrence joins from D.C. to dish on the upheaval and drama taking place at the FDA. Then, we…
1 year, 7 months ago
342: FDA cuts, zombie biotechs, and too much weight loss?
Mizuho analyst Jared Holz joins to discuss Adam's column on biotech's dark period. We also talk about Elaine's latest article on the push for greater…
1 year, 8 months ago
341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers
We bring on biotech reporter Jonathan Wosen to discuss the NIH's decision to dramatically cut funding for overhead costs paid to research institution…
1 year, 8 months ago
340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug
We bring on our colleague Jason Mast to discuss the dramatic downturn in the once-swaggering field of CRISPR gene editing. We also talk about the adv…
1 year, 8 months ago
339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad
Our colleague Rachel Cohrs Zhang joins us to break down RFK Jr.’s confirmation hearings, including some contentious questions about vaccines and auti…
1 year, 8 months ago